Recently published research from the United States and Australian reveals two ways to slow or prevent cognitive decline.
Ethical considerations explored for aducanumab in Alzheimer’s disease
Nov 19, 2021
Grounds are insufficient to offer aducanumab (Aduhelm) for moderate, advanced Alzheimer’s dementia or for individuals without biomarker evidence of brain ß-amyloid, according to a position statement.
More news for Friday, April 8
By
Kimberly Bonvissuto
Apr 08, 2022
CBRE Seniors Housing & Care Investor Survey identifies industry trends … Senior housing staffing shortages move from severe to moderate: NIC … CMS finalizes Medicare coverage policy for Alzheimer’s...
Inverse link found for antioxidant levels, all-cause dementia
May 04, 2022
Serum lutein+zeaxanthin and β-cryptoxanthin levels were inversely associated with incident all-cause dementia.
Retinal layer thickness linked to cognitive decline in older adults
May 27, 2022
Thinner baseline total macular retinal nerve fiber layer thickness was associated with a larger decline in cognitive function test scores during follow-up.
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
More news for Wednesday, March 8
Mar 07, 2017
AHCA/NCAL says Seema Verma ‘pragmatic leader we need at CMS’ … Alzheimer’s $259 billion cost could break Medicare … Head injuries can lead to Alzheimer’s, Parkinson’s...
Assisted living memory care admission reduces odds of SNF placement, acute care stays, study finds
By
Alicia Lasek
Jan 07, 2022
Older adults living with dementia who move into memory care units in assisted living communities are less likely to experience a skilled nursing facility or a hospital stay than their peers who move into...
Study identifies factors that predict driving cessation in seniors
May 22, 2024
Older age, female sex and progression to symptomatic Alzheimer’s disease were associated with driving cessation.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...